DaVita (DVA)
(Delayed Data from NYSE)
$137.72 USD
+1.77 (1.30%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $137.80 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$137.72 USD
+1.77 (1.30%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $137.80 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Top Ranked Momentum Stocks to Buy for November 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd
Shrug Off Market Gyrations With These Top 5 Value Picks
by Nalak Das
A strong rally is unlikely for as long as this trade conflict continues. However, the downside potential will be limited owing to U.S. economic strength.
Why DaVita HealthCare (DVA) Might be Well Poised for a Surge
by Zacks Equity Research
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Are Investors Undervaluing DaVita HealthCare (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for November 12th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DaVita (DVA) raises guidance for 2019 following impressive Q3 results.
DaVita HealthCare (DVA) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 24.39% and 1.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects to have gained from calcimimetics in the third quarter.
DaVita HealthCare (DVA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, integration risks remain a concern.
5 Low Price-to-Book Stocks to Increase Your Portfolio's Value
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
DVA vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. AMED: Which Stock Is the Better Value Option?
5 Buffett-Style Value Picks Boasting Impressive PEG Ratio
by Urmimala Biswas
While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.
Zacks.com featured highlights include: DaVita, Hibbett, First Horizon, Universal Forest and Popular
by Zacks Equity Research
Zacks.com featured highlights include: DaVita, Hibbett, First Horizon, Universal Forest and Popular
5 Stocks With Amazingly Low EV/EBITDA Ratios to Own Now
by Anindya Barman
We have screened value stocks based on EV/EBITDA ratio that offers a clearer picture of a company's valuation and earnings potential.
The Zacks Analyst Blog Highlights: Exantas, Chemed, Viad, Arbor Realty and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exantas, Chemed, Viad, Arbor Realty and DaVita
Strong ISM Services Index Eases Recession Fears: 5 Top Picks
by Nalak Das
The ISM Services index clearly reflects that the U.S. economy has sustained its momentum despite heightened trade conflict and global economic slowdown.
5 Price-to-Book Value Picks for September
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Why Is DaVita HealthCare (DVA) Down 5% Since Last Earnings Report?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
When to Buy Global Markets?
by John Blank
It is NOT crazy to study global markets now.
Draghi Says Goodbye. Should You Care?
by John Blank
The answer is yes. A monetary policy regime change matters.
5 Stocks From the Best Performing Sectors in Q2
by Zacks Equity Research
We have shortlisted solid stocks from the top-performing sectors in Q2 that should make a great addition to your portfolio.